#1 Clinical Trials Search in Europe

Glpg3667 Fumarate

GLPG3667 Fumarate is a promising drug currently being studied in clinical trials for its potential in treating two autoimmune conditions: dermatomyositis and systemic lupus erythematosus. These trials aim to evaluate the drug’s efficacy, safety, and tolerability in adult patients, as well as to understand its pharmacokinetics and pharmacodynamics. The studies are designed to assess the drug’s impact on disease activity, skin manifestations, and overall quality of life for patients with these challenging conditions.

Table of Contents

What is GLPG3667?

GLPG3667 FUMARATE is an investigational drug developed by Galapagos, a pharmaceutical company. It is currently being studied as a potential treatment for autoimmune diseases, specifically dermatomyositis and systemic lupus erythematosus (SLE)[1][2]. The drug is administered orally in the form of capsules.

What conditions does GLPG3667 treat?

GLPG3667 is being investigated for the treatment of two autoimmune conditions:

  1. Dermatomyositis: This is a rare inflammatory disease that causes skin rashes and muscle weakness. It can affect both adults and children[1].
  2. Systemic Lupus Erythematosus (SLE): This is a chronic autoimmune disease that can affect various parts of the body, including skin, joints, kidneys, brain, and other organs[2].

How does GLPG3667 work?

While the exact mechanism of action is not explicitly stated in the provided information, GLPG3667 is described as a tyrosine kinase 2 (TYK2) inhibitor[2]. TYK2 is an enzyme involved in the signaling of several inflammatory pathways. By inhibiting TYK2, GLPG3667 may help reduce inflammation and alleviate symptoms associated with dermatomyositis and SLE.

Current Clinical Trials

GLPG3667 is currently being evaluated in two Phase II clinical trials:

  1. Dermatomyositis Trial: This is a randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG3667 in adults with dermatomyositis. The treatment period is 24 weeks, with an additional open-label extension period[1].
  2. Systemic Lupus Erythematosus Trial: This is also a randomized, double-blind, placebo-controlled study assessing the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG3667 in adults with active SLE. The treatment period for this trial is 48 weeks[2].

Dosage and Administration

In both trials, GLPG3667 is administered orally once daily. The maximum daily dose being tested is 150 mg[1][2]. In the SLE trial, a lower dose of 75 mg is also being evaluated[2].

Efficacy

The efficacy of GLPG3667 is being evaluated through various measures:

  • For dermatomyositis: The primary endpoint is the proportion of subjects with at least minimal improvement according to the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria[1].
  • For SLE: The primary endpoint is the proportion of subjects who achieve the SLE Responder Index (SRI)-4 response at Week 32[2].

Additional efficacy measures include changes in disease activity scores, skin disease activity, health-related outcomes, and muscle strength[1][2].

Safety and Side Effects

As GLPG3667 is still in clinical trials, comprehensive safety data is not yet available. The trials are monitoring for treatment-emergent adverse events (TEAEs), serious adverse events, and adverse events leading to treatment discontinuation[1][2]. Patients should be aware that unexpected side effects may occur during the trial.

Who is eligible for GLPG3667 treatment?

Eligibility criteria for the clinical trials include:

  • Adults aged 18-75 years
  • Diagnosed with either dermatomyositis or active SLE
  • Meeting specific disease activity criteria
  • For dermatomyositis: Previous failure or intolerance to first-line treatments
  • For SLE: Positive for certain autoantibodies and meeting specific disease manifestation criteria

Exclusion criteria include certain medical conditions, prior treatments, and pregnancy[1][2].

Conclusion

GLPG3667 FUMARATE is a promising investigational drug for the treatment of dermatomyositis and systemic lupus erythematosus. While still in clinical trials, it offers hope for patients with these challenging autoimmune conditions. As research progresses, more information about its efficacy and safety profile will become available.

Aspect Dermatomyositis Trial Systemic Lupus Erythematosus Trial
Study Design Randomized, double-blind, placebo-controlled Randomized, double-blind, placebo-controlled
Duration 24 weeks 48 weeks
Primary Endpoint Proportion of subjects with at least minimal improvement according to ACR/EULAR criteria Proportion of subjects who achieved SRI-4 response at Week 32
Key Secondary Endpoints Changes in m-CDASI-A, HAQ-DI, MMT-8 SRI-4 at Week 48, BICLA response, CLASI-A reduction, LLDAS achievement
Safety Assessments Frequency and severity of TEAEs, SAEs, and TEAEs leading to discontinuation TEAEs, SAEs, and TEAEs leading to discontinuation
Pharmacokinetic Assessments Cmax, AUC, and Ctrough at steady-state Cmax, AUC, and Ctrough at steady-state
Key Inclusion Criteria Probable or definite DM, active disease, previous treatment failure or intolerance SLE diagnosis, SLEDAI-2K score ≥6, positive ANA or anti-dsDNA or anti-Sm
Key Exclusion Criteria Cancer-associated myositis, other causes of myositis, permanent muscle weakness Active severe lupus nephritis, poorly controlled chronic diseases, prior TYK2 inhibitor exposure

FAQ

  • What is GLPG3667 Fumarate? GLPG3667 Fumarate is an investigational drug being studied for its potential to treat autoimmune conditions such as dermatomyositis and systemic lupus erythematosus. It is administered orally in capsule form.
  • What conditions are being studied in these clinical trials? The clinical trials are focusing on two autoimmune conditions: dermatomyositis and systemic lupus erythematosus (SLE). These are both complex diseases that affect the immune system and can cause various symptoms throughout the body.
  • How is the effectiveness of GLPG3667 Fumarate being measured? The effectiveness is being measured through various means, including improvements in disease activity scores, skin condition assessments, muscle strength tests, and quality of life measures. For SLE, specific measures like the SLE Responder Index (SRI-4) and the BILAG-based Composite Lupus Assessment (BICLA) are being used.
  • What are the main goals of these clinical trials? The main goals of these trials are to evaluate the efficacy of GLPG3667 Fumarate compared to placebo, assess its safety and tolerability, and understand how the drug behaves in the body (pharmacokinetics) of patients with dermatomyositis or SLE.
  • Who can participate in these clinical trials? Generally, adults aged 18 to 75 years with a confirmed diagnosis of either dermatomyositis or systemic lupus erythematosus may be eligible. However, there are specific inclusion and exclusion criteria for each trial, including disease activity levels, previous treatments, and other health conditions that may affect eligibility.

Ongoing Clinical Trials on Glpg3667 Fumarate

  • Study of GLPG3667 for Adults with Active Systemic Lupus Erythematosus

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria France Germany Hungary Poland Spain

  • Study on the Effects of GLPG3667 for Adults with Dermatomyositis

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Croatia Czechia France Germany +4

Glossary

  • Dermatomyositis: A rare autoimmune disease characterized by muscle weakness and a distinctive skin rash.
  • Systemic Lupus Erythematosus (SLE): A chronic autoimmune disease that can affect various parts of the body, including skin, joints, kidneys, brain, and other organs.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and relationship between drug concentration and effect.
  • Placebo: An inactive substance used in clinical trials to compare the effects of a drug against no treatment.
  • Efficacy: The ability of a drug to produce the desired therapeutic effect.
  • SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index 2000, a tool used to measure disease activity in lupus patients.
  • BILAG: British Isles Lupus Assessment Group, a system used to assess disease activity in different organ systems affected by lupus.
  • SRI-4: SLE Responder Index 4, a composite measure used to evaluate the response to treatment in lupus patients.
  • BICLA: BILAG-based Composite Lupus Assessment, another measure used to evaluate treatment response in lupus patients.
  • CLASI: Cutaneous Lupus Erythematosus Disease Area and Severity Index, a tool used to assess the severity of skin involvement in lupus.
  • Immunosuppressant: A type of medication that suppresses or reduces the strength of the body's immune system.
  • Corticosteroids: A class of steroid hormones used to treat inflammation in various conditions, including autoimmune diseases.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-glpg3667-for-adults-with-dermatomyositis/
  2. http://clinicaltrials.eu/trial/study-of-glpg3667-for-adults-with-active-systemic-lupus-erythematosus/